Naloxone - CAS 465-65-6
Catalog number:
465-65-6
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C19H21NO4
Molecular Weight:
327.37
COA:
Inquire
Targets:
Others
Description:
Naloxone is a medication used to block the effects of opioids, especially in overdose useful both in acute opioid overdose and in reducing respiratory or mental depression due to opioids.
Publictions citing BOC Sciences Products
  • >> More
Purity:
≥98%
Appearance:
White to slightly off-white powder
Synonyms:
17-Allyl-4,5α-epoxy-3,14-dihydroxy-morphinan-6-one; (5α)-4,5-Epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one; N-Allyl-7,8-dihydro-14-hydroxynormorphinone, (7CI); (-)-Naloxone; 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro[4,5-bcd]furan-5(6H)-one;
Solubility:
Soluble in DMSO
Storage:
Store at -20 °C
MSDS:
Inquire
Application:
Block the effects of opioids, especially in overdose
Quality Standard:
Enterprise standard
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly.
Quantity:
Milligrams-Grams
Boiling Point:
532.8ºC at 760 mmHg
Melting Point:
184 ºC
Density:
1.43 g/cm3
InChIKey:
UZHSEJADLWPNLE-GRGSLBFTSA-N
InChI:
InChI=1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1
Canonical SMILES:
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O
1.Evaluation of the Overdose Education and Naloxone Distribution Program of the Baltimore Student Harm Reduction Coalition.
Lewis DA1, Park JN1, Vail L1, Sine M1, Welsh C1, Sherman SG1. Am J Public Health. 2016 Apr 14:e1-e4. [Epub ahead of print]
Although historically the majority of overdose education and naloxone distribution (OEND) programs have targeted opioid users, states are increasingly passing laws that enable third-party prescriptions of naloxone to individuals who may be able to respond to an overdose, including friends and family members of individuals who use opioids. In this report, we discuss the Baltimore Student Harm Reduction Coalition (BSHRC) OEND program, Maryland's first community-based, state-authorized training program under a new law allowing third-party naloxone prescription. In an 8-month pilot period, 250 free naloxone kits were distributed, and 3 overdose reversals were reported to BSHRC. Trainings were effective in increasing self-efficacy surrounding overdose prevention and response, which appears to persist at up to 12 months following the training. (Am J Public Health. Published online ahead of print April 14, 2016: e1-e4. doi:10.2105/AJPH.2016.303141).
2.Targinact for restless legs syndrome.
Drug Ther Bull. 2016 Apr;54(4):42-5. doi: 10.1136/dtb.2016.4.0393.
Idiopathic restless legs syndrome (RLS)-also known as Willis-Ekbom disease-is a neurological condition characterised by an overwhelming urge to move the legs, occurring during rest or inactivity, especially at night.(1-3)Symptoms are highly variable in frequency and severity, and can affect sleep and quality of life. First-line management includes addressing precipitating or aggravating factors and providing explanation, reassurance and advice on self-help strategies.(4-9)Drug therapy (e.g. a dopamine agonist) is used for patients with more severe symptoms.(6)In December 2014, the marketing authorisation for a modified-release preparation containing oxycodone and naloxone (Targinact-Napp Pharmaceuticals) was expanded to include use in the treatment of severe to very severe RLS after failure of dopaminergic therapy.(10)Here we review the management of adults with RLS, including the place of oxycodone/naloxone.
3.Safety concerns with long-term opioid use.
Harned M1, Sloan P1. Expert Opin Drug Saf. 2016 Apr 12. [Epub ahead of print]
INTRODUCTION: The benefits of opioid therapy must be balanced by any adverse effects. In recent years, prescription opioids have been increasingly prescribed, but have also been associated with increased abuse, overdose and death. Areas Covered: This review will categorize the common risks of opioid administration. Recognized adverse effects of opioid therapy include constipation, tolerance, endocrinopathies, sleep disorders, cognitive effects, respiratory depression, overdose and addiction. Studies have shown that there is increased risk of overdose and death with higher daily opioid doses, particularly above a morphine equivalent oral daily dose of 100 milligrams. Extended-release/long acting (ER/LA) opioid formulations may be beneficial for the compliant patient, yet may expose a higher risk for abuse if used inappropriately since each tablet carries a larger dose of medication. Expert Opinion: Prospective, controlled one-year trials are needed to establish the efficacy and safety profile of chronic opioid therapy.
4.Findings and lessons learnt from implementing Australia's first health service based take-home naloxone program.
Chronister KJ1,2, Lintzeris N3,4, Jackson A1,3, Ivan M1,2, Dietze P5, Lenton S6, Kearley J1,3, van Beek I1,7. Drug Alcohol Rev. 2016 Apr 13. doi: 10.1111/dar.12400. [Epub ahead of print]
INTRODUCTION AND AIMS: Opioid overdose prevention programs providing take-home naloxone have been expanding internationally. This paper summarises findings and lessons learnt from the Overdose Prevention and Emergency Naloxone Project which is the first take-home naloxone program in Australia implemented in a health care setting.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 115436-72-1 Risedronate Sodium

Risedronate Sodium
(CAS: 115436-72-1)

Risedronate Sodium is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone.

CAS 73030-71-4 Atractylenolide III

Atractylenolide III
(CAS: 73030-71-4)

Atractylenolide III is a major component of Atractylodes rhizome, which can induce apoptosis of the lung carcinoma cells.

CAS 6537-80-0 Chicoric acid

Chicoric acid
(CAS: 6537-80-0)

Chicoric Acid, a natural product, is reported to be antioxidative, is an effective inhibitor of human immunodeficiency virus type-1 (HIV-1) integrase and the re...

CAS 1016535-83-3 MDK35833

MDK35833
(CAS: 1016535-83-3)

MDK35833, also called as Oct3/4-inducer-1, is a potent Oct3/4-inducer, which enhances its transcriptional activity in diverse human somatic cells, implying the ...

CAS 51-48-9 L-Thyroxine

L-Thyroxine
(CAS: 51-48-9)

L-Thyroxine is a synthetic form of thyroxine and a hormone replacement drug.

CAS 382-45-6 Adrenosterone

Adrenosterone
(CAS: 382-45-6)

Adrenosterone is a steroid hormone with weak androgenic effect. It is thought to be a competitive selective 11βHSD1inhibitor, which is responsible for activatio...

CAS 479-92-5 Isopropylantipyrinum

Isopropylantipyrinum
(CAS: 479-92-5)

Isopropylantipyrinum is a derivative of phenazone with similar analgesic and antipyretic effects.

CAS 6893-02-3 3,3,5-Triiodo-L-thyronine

3,3,5-Triiodo-L-thyronine
(CAS: 6893-02-3)

3,3,5-Triiodo-L-thyronine(T3), an active metabolite of Thyroxine, could be effective in agonizing both thyroid hormone receptors TRα and TRβ so that might help ...

CAS 435-97-2 Phenprocoumon

Phenprocoumon
(CAS: 435-97-2)

Phenprocoumon, a derivative of coumarin, is known for being an oral anti-coagulant.

BMS-247243
(CAS: 307316-55-8)

BMS-247243 is a novel β-Lactamase inhibitor which is a family of enzymes involved in bacterial resistance to beta-lactam antibiotics.

DAA-1106
(CAS: 220551-92-8)

DAA-1106, with anxiolytic effects in mice, is a selective ligand for peripheral benzodiazepine receptor (PBR) and a selective agonist at the peripheral benzodia...

CAS 12192-57-3 Aurothioglucose

Aurothioglucose
(CAS: 12192-57-3)

Aurothioglucose is used in the treatment of rheumatoid arthritis and psoriasis.

CAS 175135-47-4 O4I1

O4I1
(CAS: 175135-47-4)

O4I1 is a potent inducer of Oct3/4. O4I1 enhanced Oct3/4 expression. O4I1 not only promoted expression and stabilization of Oct3/4 but also enhanced its transcr...

CAS 133-67-5 Trichlormethiazide

Trichlormethiazide
(CAS: 133-67-5)

Trichlormethiazide is a diuretic with properties similar to those of hydrochlorothiazide.

CAS 2920-86-7 Prednisolone hemisuccinate

Prednisolone hemisuccinate
(CAS: 2920-86-7)

Prednisolone hemisuccinate is a metabolite of a derivative of cortisol called Prednisolone. It can be used to treat a variety of inflammatory and auto-immune co...

CAS 119515-38-7 Picaridin

Picaridin
(CAS: 119515-38-7)

Picaridin,also known as Icaridin, KBR 3023, under the INCI name hydroxyethyl isobutyl piperidine carboxylate, and the trade names Bayrepel and Saltidin, is an i...

CAS 1018675-35-8 CVT-12012

CVT-12012
(CAS: 1018675-35-8)

CVT-12012 is a bio-active chemical compound and is highly potent in a human cell-based (HEPG2) SCD assay with IC50 value of 6nM.

CAS 4431-01-0 Ligustilide

Ligustilide
(CAS: 4431-01-0)

Ligustilide not only has an active dilatory effect on myometrium but also an effective role in reducing the neurogenic and inflammatory pain, thus having the po...

ONO EI-601
(CAS: 155023-59-9)

ONO EI-601, a sulfonylamine derivative, is one metabolite of ONO-5046 which is a neutrophil elastase inhibitor that could be effective against acute lung injury...

CAS 79551-86-3 20-Hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoic acid

20-Hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraen
(CAS: 79551-86-3)

20-Hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoic acid is a potent vasoconstrictor produced in vascular smooth muscle cells. Its EC50 value is < 10 nM. It is a cytoch...

Chemical Structure

CAS 465-65-6 Naloxone

Quick Inquiry

Verification code

Featured Items